Welcome to our dedicated page for Biovaxys Technol news (Ticker: BVAXF), a resource for investors and traders seeking the latest updates and insights on Biovaxys Technol stock.
Company Overview
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company registered in British Columbia, Canada, that focuses on advanced immunotherapies using its proprietary DPX™ immune-educating platform and HapTenix© 'neoantigen' tumor cell construct technology. These innovative platforms are designed to orchestrate targeted, robust, and persistent antigen-specific immune responses, addressing complex challenges in oncology, infectious diseases, and antigen desensitization.
Core Technology and Platforms
The cornerstone of BioVaxys’ approach is the DPX™ platform, a non-aqueous, lipid-in-oil delivery system that facilitates the steady recruitment of antigen presenting cells (APCs) to the injection site. This ensures that antigens—whether peptides, proteins, mRNA, or small molecules—are retained in a manner that promotes prolonged immune stimulation. The unique, 'no release' mechanism of DPX™ contrasts with conventional aqueous or emulsion-based formulations by delivering antigens in a concentrated, targeted fashion.
Complementing DPX™ is the HapTenix© platform, which enables the design of personalized immunotherapeutic vaccines targeting tumor-specific neoantigens. Through these integrated systems, BioVaxys is able to package multiple antigens, supporting research and clinical development across a wide array of therapeutic areas.
Clinical Pipeline and Therapeutic Areas
BioVaxys is currently involved in pioneering clinical studies with its immunotherapeutic candidates. Its portfolio spans several indications including:
- Oncology: Development of vaccine formulations for cancers such as advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL), platinum resistant ovarian cancer, and other tumor types, leveraging both the DPX™ and HapTenix© platforms.
- Infectious Diseases: Utilization of the DPX™ platform in developing vaccines that drive both T cell and B cell responses to combat viral infections, including respiratory pathogens.
- Antigen Desensitization: Addressing immunological disorders through novel approaches that modulate immune responses, with potential applications for food allergies and other conditions.
Market Position and Competitive Landscape
Within the competitive biopharmaceutical landscape, BioVaxys distinguishes itself by integrating a flexible antigen delivery system with targeted immune activation. The company's reliance on robust intellectual property, including patents for low dose volume delivery of B-cell epitopes and innovative formulations, underpins its strategy for partnering and co-development. While challenges such as regulatory approvals and clinical validation are inherent in the biopharmaceutical sector, BioVaxys’ strategic focus on technology-driven immunotherapies positions it as a significant contributor to the evolving field of vaccine technology.
Operational and Business Model Insights
BioVaxys generates value not solely through its clinical programs but also by leveraging its extensive IP portfolio and establishing strategic partnerships. This includes collaborations that extend the application of its proprietary platforms to diverse areas, from animal health (via licensed technologies) to human therapeutic applications. The company operates with a clear emphasis on scientific innovation, rigorous clinical development, and the safeguarding of its intellectual properties, which collectively enhance industry trust and credibility.
Scientific and Technological Credibility
Through numerous preclinical studies and early clinical trials, BioVaxys has demonstrated its capacity to induce sustained immune responses across multiple therapeutic modalities. The depth of their research is supported by detailed immunogenicity assessments and comparative studies illustrating the advantages of the DPX™ platform over traditional delivery methods. This scientific rigor serves as the foundation for future research collaborations and validates their standing as experts in the field of immune-educating technologies.
Conclusion
BioVaxys Technology Corp. offers a comprehensive, technology-driven approach to immunotherapy development, underpinned by its innovative DPX™ and HapTenix© platforms. By addressing key limitations of traditional delivery systems and fostering strategic collaborations, the company continues to contribute valuable insights and solutions within the biopharmaceutical industry. Its emphasis on robust intellectual property, scientific excellence, and methodical clinical development makes it a noteworthy entity for those seeking detailed, unbiased information on cutting-edge immunotherapeutics.
BioVaxys Technology Corp. (BVAXF) highlights the potential of its DPX™ lipid-in-oil delivery platform for vaccines across multiple infectious diseases. Key findings include:
1) In a Phase 1 RSV study, 93% of subjects developed antigen-specific immune responses, with 100% maintaining immunity after one year in the 25μg dose group.
2) A DPX-based anthrax vaccine showed 100% immunity from a single injection in animal studies.
3) For influenza, DPX-rHA achieved higher antibody levels than standard Alum rHA vaccines and protected against multiple flu strains in preclinical studies.
BioVaxys is seeking partnerships to further develop these promising vaccine candidates targeting RSV, anthrax, influenza, and other infectious diseases.
BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) and SpayVac for Wildlife, Inc. have announced the completion of SpayVac's new research and production facility in Madison, Wisconsin. The facility will produce long-lasting, single-dose veterinary contraceptive vaccines using a patented liposome-based antigen delivery platform technology licensed from BioVaxys. These vaccines aim to address fertility control needs in wildlife, agricultural production animals, and aquaculture markets.
SpayVac relocated from the University of Victoria, British Columbia, to Madison with support from the BrightStar Wisconsin Foundation and angel investors. The new laboratory will enhance the company's ability to develop new vaccine formulations for various species. SpayVac plans to commercialize fertility control vaccines for deer, horses, and other animals, with regulatory approval filing expected in 2025 and subsequent commercial sales generating royalty revenue for BioVaxys.
BioVaxys Technology Corp. (OTCQB: BVAXF) has signed a binding Letter of Intent with AP Visionaries, Inc. to jointly develop a DPX™-based therapy for life-threatening food allergies, specifically peanut/tree nuts and eggs. The collaboration involves The Schroeder Allergy and Immunology Research Institute at McMaster University. BioVaxys will fund the study and retain intellectual property rights, while APVI will receive royalties and milestone payments.
The global peanut allergy treatment market is expected to reach USD 1.01 billion by 2030, growing at a CAGR of 11.82% from 2024 to 2030. Peanut allergies affect about 1.2% of the US population and 2.5% of children, with an estimated annual economic cost of $24.8 billion for food allergies in US children.
The DPX™ platform's flexibility and immune-educating capability offer potential advantages over current treatments, which often require frequent dosing and carry risks of anaphylaxis.
BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) has been issued U.S. Patent No. 12,042,537 by the USPTO for inducing an antibody immune response using a low dose volume delivery of a B-cell epitope formulated with DPX™. This proprietary lipid-based delivery platform allows for a robust and long-duration immune response. The technology enables delivery of less than 100 µl, packaging 5-50 µL of an antigen.
Potential applications include epitope-based vaccines for chronic hepatitis-B, influenza, and RSV. A previous Phase 1 study of DPX-RSV showed promising results, with 93% of participants maintaining antigen-specific immune responses after nine months. This patent issuance strengthens BioVaxys' position for further development and potential partnerships in epitope-based vaccine development.
BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) has engaged Brittany Davison, CPA, CA as Business Advisor. Ms. Davison, owner of Davison CPA Consulting Inc., previously served as Chief Accounting Officer and Acting CFO at IMV Inc., where she led a US$9M Public Offering and assisted in raising over US$165M. She was instrumental in IMV Inc.'s Nasdaq listing in 2018 and involved in business development and investor relations. At BioVaxys, Ms. Davison will assist with knowledge transfer of former IMV Inc. assets, support investor relations, business development, and facilitate private funding, government funding, and SR&ED tax incentives.
BioVaxys Technology Corp. (BVAXF) and SpayVac-for-Wildlife, Inc. have announced a trial to test SpayVac®, a long-lasting, single-dose contraceptive vaccine, in captive Asian elephants. The trial, conducted in partnership with Chiang Mai University in Thailand, aims to address concerns about human-elephant conflicts and ecological impacts due to confined elephant populations. SpayVac utilizes BioVaxys' patented liposome-based antigen delivery platform, which has shown sustained immune responses in various species.
The research, which began in April, will track reproductive cycling, contraceptive efficacy, and antibody titers over a 5-year period. A previous trial with African elephants demonstrated elevated antibody titers for at least 7 years after a single dose. SpayVac is also planning to commercialize fertility control vaccines for other animals using the same technology.
BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTC: BVAXF) announced the revocation of a cease trade order issued by the Ontario Securities Commission (OSC) on May 15, 2024. The order was due to delays in filing audited annual financial statements for the year ended October 31, 2023, and interim financial statements for the three months ended January 31, 2024. The company has now completed these filings, along with interim financial statements for the six months ended April 30, 2024. The OSC confirmed the order revocation on July 11, 2024, with all filings available on SEDAR+.
BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) has been issued a Failure-to-File Cease Trade Order (FFCTO) by the Ontario Securities Commission (OSC) due to delays in filing required financial statements and discussions for the fiscal year ending October 31, 2023, and the three months ending January 31, 2024. The FFCTO, effective May 15, 2024, prohibits any trading of BioVaxys securities in Canada. The company missed deadlines of February 28, 2024, for annual filings and April 1, 2024, for interim filings. They are working to complete these filings soon and expect the FFCTO to be lifted once compliance is achieved.
BioVaxys Technology Corp. appoints Christopher Cherry as Chief Financial Officer, bringing extensive experience in financial management. The company anticipates significant growth following the recent acquisition of IMV Intellectual Property.
FAQ
What is the current stock price of Biovaxys Technol (BVAXF)?
What is the market cap of Biovaxys Technol (BVAXF)?
What is the core technology behind BioVaxys Technology Corp.?
Which therapeutic areas does the company focus on?
How does the DPX™ platform differ from conventional vaccine formulations?
What is the role of the HapTenix© platform?
How does BioVaxys generate revenue?
What kind of partnerships does BioVaxys pursue?
How is BioVaxys positioned within the competitive biopharmaceutical landscape?
What are the benefits of using the DPX™ platform?
